预测慢性乙型肝炎停药后复发的血清学标志物研究进展  

Research Progress in Serological Markers for Predicting Relapse of Chronic Hepatitis B after Discontinuation of Medication

作　　者：吴倩君 吴迪 韩梅芳[1] WU Qianjun;WU Di;HAN Meifang(Department of Infectious Disease,Tongji Hospital,Tongji Medical College of Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院感染科,武汉430030

出　　处：《医学综述》2023年第14期2794-2800,共7页Medical Recapitulate

基　　金：国家自然科学基金(82202502)。

摘　　要：慢性乙型肝炎(CHB)是威胁我国的重大公共卫生问题,临床最常用的治疗方案包括核(苷)酸类似物及聚乙二醇干扰素治疗。然而,由于宿主体内乙型肝炎病毒(HBV)共价闭合环状DNA无法彻底清除,以及宿主体内HBV DNA整合等原因,部分CHB患者停用抗病毒药物后仍存在病毒学复发以及临床复发的风险。目前,临床常用的检测指标难以精准评估CHB患者停药后的复发风险。因此,临床工作中迫切需要寻找新型血清学标志物,全面反映CHB患者的抗病毒治疗效果,评估停药后复发的风险。Chronic hepatitis B(CHB)is a threat to major public health problems in China.The most commonly used clinical treatment includes nucleotide analogues and pegylated interferon therapy.However,due to the difficulty of complete elimination of covalently closed circular DNA of hepatitis B virus(HBV)and HBV DNA integration in the host,some patients with CHB still have the risk of virological relapse and clinical relapse after discontinuation of antiviral drugs.The current commonly used clinical indicators are difficult to accurately assess the risk of relapse in patients with CHB after drug withdrawal.Therefore,there is an urgent need in clinical work to search for novel serological markers,to fully reflect the efficacy of antiviral therapy in patients with CHB,and evaluate the risk of relapse after drug withdrawal.

关 键 词：慢性乙型肝炎 血清学标志物 临床治愈 病毒学复发 临床复发 

分 类 号：R512.62[医药卫生—内科学]